Fagron, the leading global player in pharmaceutical compounding, is pleased to announce a strategic acquisition that will significantly reinforce its presence in North America. The company has signed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder specializing in the health and wellness segment in California, whilst adhering to a disciplined acquisition strategy. UCP, based in San Diego, the U.S., is a 503A pharmaceutical compounder specializing in the health and wellness segment, with strong positions in hormones and urology and a solid compliance record, making it highly complementary to Anazao and enabling a differential coast-to-coast offering.
Read the full article: Fagron Announces the Acquisition of UCP in North America //
Source: https://www.globenewswire.com/news-release/2025/09/25/3155963/0/en/Fagron-announces-the-acquisition-of-UCP-in-North-America-and-FDA-inspection-update.html